BCG vaccine: Difference between revisions
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult====== | |fdaLIADAdult======Tuberculosis; Prophylaxis===== | ||
* | *'''BCG VACCINE (TICE® strain) is indicated for the prevention of tuberculosis in persons not previously infected with M. tuberculosis who are at high risk for exposure. As with any vaccine, immunization with BCG VACCINE may not protect 100% of susceptible individuals.''' | ||
'''The Advisory Committee on Immunization Practices (ACIP) and the Advisory Committee for the Elimination of Tuberculosis has recommended that BCG vaccination be considered in the following circumstances.''' | |||
'''TB Exposed Tuberculin Skin Test-Negative Infants and Children''' | |||
*BCG vaccination is recommended for infants and children with negative tuberculin skin tests who are (a) at high risk of intimate and prolonged exposure to persistently untreated or ineffectively treated patients with infectious pulmonary tuberculosis and who cannot be removed from the source of exposure and cannot be placed on long-term primary preventive therapy, or (b) continuously exposed to persons with infectious pulmonary tuberculosis who have bacilli resistant to isoniazid and rifampin, and the child cannot be separated from the presence of the infectious patient. | |||
'''TB Exposed Health Care Workers (HCW) in High Risk Settings''' | |||
* | *BCG vaccination of HCWs should be considered on an individual basis in settings where (a) a high percentage of TB patients are infected with M. tuberculosis strains resistant to both isoniazid and rifampin, (b) transmission of such drug resistant M. tuberculosis strains to HCWs and subsequent infection are likely, and (c) comprehensive TB infection control precautions have been implemented and have not been successful. Vaccination should not be required for employment or for assignment of HCWs in specific work areas. HCWs considered for BCG vaccination should be counseled regarding the risks and benefits associated with both BCG vaccinations and TB preventive therapy. | ||
'''Exposed Health Care Workers in Low Risk Settings''' | |||
*BCG vaccination is not recommended for HCWs in settings in which the risk for M. tuberculosis transmission is low. | |||
* Dosing Information | * Dosing Information | ||
Line 33: | Line 37: | ||
:* Dosage | :* Dosage | ||
==== | ====Carcinoma in situ of bladder; Treatment and Prophylaxis==== | ||
* Dosing Information | * Dosing Information | ||
Line 39: | Line 43: | ||
:* Dosage | :* Dosage | ||
====Malignant tumor of urinary bladder, Stage Ta and/or T1 papillary tumors following transurethral resection; Prophylaxis==== | |||
* Dosing Information | * Dosing Information | ||
Line 54: | Line 49: | ||
:* Dosage | :* Dosage | ||
<!--Off-Label Use and Dosage (Adult)--> | |||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | <!--Guideline-Supported Use (Adult)--> | ||
|offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
<!--Non–Guideline-Supported Use (Adult)--> | <!--Non–Guideline-Supported Use (Adult)--> | ||
|offLabelAdultNoGuideSupport= | |offLabelAdultNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
* | |||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
<!--Pediatric Indications and Dosage--> | <!--Pediatric Indications and Dosage--> | ||
<!--FDA-Labeled Indications and Dosage (Pediatric)--> | <!--FDA-Labeled Indications and Dosage (Pediatric)--> | ||
|fdaLIADPed====== | |fdaLIADPed======Tuberculosis; Prophylaxis===== | ||
* Dosing Information | * Dosing Information |
Revision as of 17:52, 16 December 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
BCG vaccine is an immunologic adjuvant that is FDA approved for the prophylaxis of tuberculosis in persons not previously infected with M. tuberculosis who are at high risk for exposure. Common adverse reactions include percutaneous injection site reaction, nausea, axillary or cervical lymphadenopathy, , induration, cystitis, dysuria, hematuria, increased frequency of urination, urgent desire to urinate, influenza-like illness, malaise, shivering.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Tuberculosis; Prophylaxis
- BCG VACCINE (TICE® strain) is indicated for the prevention of tuberculosis in persons not previously infected with M. tuberculosis who are at high risk for exposure. As with any vaccine, immunization with BCG VACCINE may not protect 100% of susceptible individuals.
The Advisory Committee on Immunization Practices (ACIP) and the Advisory Committee for the Elimination of Tuberculosis has recommended that BCG vaccination be considered in the following circumstances.
TB Exposed Tuberculin Skin Test-Negative Infants and Children
- BCG vaccination is recommended for infants and children with negative tuberculin skin tests who are (a) at high risk of intimate and prolonged exposure to persistently untreated or ineffectively treated patients with infectious pulmonary tuberculosis and who cannot be removed from the source of exposure and cannot be placed on long-term primary preventive therapy, or (b) continuously exposed to persons with infectious pulmonary tuberculosis who have bacilli resistant to isoniazid and rifampin, and the child cannot be separated from the presence of the infectious patient.
TB Exposed Health Care Workers (HCW) in High Risk Settings
- BCG vaccination of HCWs should be considered on an individual basis in settings where (a) a high percentage of TB patients are infected with M. tuberculosis strains resistant to both isoniazid and rifampin, (b) transmission of such drug resistant M. tuberculosis strains to HCWs and subsequent infection are likely, and (c) comprehensive TB infection control precautions have been implemented and have not been successful. Vaccination should not be required for employment or for assignment of HCWs in specific work areas. HCWs considered for BCG vaccination should be counseled regarding the risks and benefits associated with both BCG vaccinations and TB preventive therapy.
Exposed Health Care Workers in Low Risk Settings
- BCG vaccination is not recommended for HCWs in settings in which the risk for M. tuberculosis transmission is low.
- Dosing Information
- Dosage
Carcinoma in situ of bladder; Treatment and Prophylaxis
- Dosing Information
- Dosage
Malignant tumor of urinary bladder, Stage Ta and/or T1 papillary tumors following transurethral resection; Prophylaxis
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
- There is limited information regarding Off-Label Guideline-Supported Use of BCG vaccine in adult patients.
Non–Guideline-Supported Use
- There is limited information regarding Off-Label Non–Guideline-Supported Use of BCG vaccine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Tuberculosis; Prophylaxis
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of BCG vaccine in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of BCG vaccine in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of BCG vaccine in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of BCG vaccine in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of BCG vaccine in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of BCG vaccine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of BCG vaccine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of BCG vaccine with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of BCG vaccine with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of BCG vaccine with respect to geriatric patients.
Gender
There is no FDA guidance on the use of BCG vaccine with respect to specific gender populations.
Race
There is no FDA guidance on the use of BCG vaccine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of BCG vaccine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of BCG vaccine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of BCG vaccine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of BCG vaccine in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of BCG vaccine in the drug label.
- Description
IV Compatibility
There is limited information regarding IV Compatibility of BCG vaccine in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of BCG vaccine in the drug label.
Pharmacology
There is limited information regarding BCG vaccine Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of BCG vaccine in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of BCG vaccine in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of BCG vaccine in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of BCG vaccine in the drug label.
How Supplied
Storage
There is limited information regarding BCG vaccine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::BCG vaccine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::BCG vaccine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of BCG vaccine in the drug label.
Precautions with Alcohol
- Alcohol-BCG vaccine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=BCG vaccine |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}} |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=BCG vaccine |Label Name=BCG vaccine11.png
}}
{{#subobject:
|Label Page=BCG vaccine |Label Name=BCG vaccine11.png
}}